Figure 4.
Survival outcomes for patients in AML19v2. (A) EFS for all patients in the Midotarg substudy. (B) EFS by randomization (DAGO1+m vs DAGO2+m). (C) OS for all patients in the Midotarg substudy. (D) OS by GO randomization (DAGO1+m vs DAGO2+m).
Survival outcomes for patients in AML19v2. (A) EFS for all patients in the Midotarg substudy. (B) EFS by randomization (DAGO1+m vs DAGO2+m). (C) OS for all patients in the Midotarg substudy. (D) OS by GO randomization (DAGO1+m vs DAGO2+m).
